Clinical Trial

PillSense Use in Anemia and Hemoccult

Study acronym: PillSense™
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated April 27, 2026 (before its estimated May 14, 2026 completion). Its status may not reflect the trial's current state.
Summary
In this study, participants will be offered a PillSense™ capsule, a small capsule to swallow, which can detect the presence of blood in the upper digestive tract within about 10 minutes. The results of this capsule test will not alter the current care plan but will help us assess whether PillSense™ can be used in the future as a standalone test to determine if it is safe for patients to be discharged with anemia or a positive stool test without other signs of gastrointestinal bleeding. This study aims to collect data that will help determine if the PillSense™ capsule could one day reduce the need for more invasive procedures while hospitalized, like endoscopy, and ensure safe patient discharge.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-29; most recent amendment 2026-04-23.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-05-23
Trial Details
NCT Number NCT06951490
Lead Sponsor AdventHealth
Collaborators: EnteraSense Limited
Conditions Occult Gastrointestinal Bleeding, Upper Gastrointestinal Bleeding (UGIB)
Enrollment 20 participants
Start Date 2025-05-15
Primary Completion 2026-05-14 (estimated)
Study Completion 2027-06-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-27